Volume 11.26 | Jul 7

2020-07-07 | HN 11.26
Hematopoiesis News by STEMCELL Technologies
Vol. 11.26 – 7 July, 2020

Single Cell Analyses and Machine Learning Define Hematopoietic Progenitor and HSC-Like Cells Derived from Human PSCs

To define the dynamics and heterogeneity of hematopoietic stem and progenitor cells (HSPCs) that can be generated in vitro from human pluripotent stem cells, scientists exploited single cell RNA sequencing in combination with single cell protein expression analysis.


How are humanized mouse models facilitating in vivo studies of hematopoiesis? Webinar by Dr. Satiro De Oliveria, UCLA
PUBLICATIONSRanked by the impact factor of the journal

Hematopoietic Stem Cells Acquire Survival Advantage by Loss of RUNX1 Methylation Identified in Familial Leukemia

The authors performed targeted deep sequencing on a family with three occurrences of acute myeloid leukemia and identified a novel RUNX1 mutation R237K.


Engineering Monocyte/Macrophage−Specific Glucocerebrosidase Expression in Human Hematopoietic Stem Cells Using Genome Editing

Scientists report an efficient CRISPR/Cas9-based approach that targeted glucocerebrosidase expression cassettes with a monocyte/macrophage-specific element to the CCR5 safe-harbor locus in human hematopoietic stem and progenitor cells.
[Nature Communications]

Full Article

Regulation of ABO Blood Group Antigen Expression by miR ‐331‐3p and miR ‐1908‐5p during Hematopoietic Stem Cell Differentiation

Researchers found that overexpression of these miRNAs in hematopoietic stem cells led to a significantly reduced number of blood group A antigens per red blood cell.
[Stem Cells]

Full Article

Effect of Sirolimus Levels between Days 11 and 20 after Allogeneic Stem Cell Transplantation on the Risk of Hepatic Sinusoidal Obstruction Syndrome

Scientists analyzed 260 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation following myeloablative conditioning using total body irradiation-based or chemotherapy only regimens, with sirolimus plus tacrolimus for graft-versus-host disease prophylaxis.
[Bone Marrow Transplantation]


Etoposide-Mediated Interleukin-8 Secretion from Bone Marrow Stromal Cells Induces Hematopoietic Stem Cell Mobilization

Investigators assessed the mechanism of hematopoietic stem cell mobilization using etoposide with granulocyte-colony stimulating factor (G-CSF), and determined how this mechanism differs from that induced by cyclophosphamide with G-CSF or G-CSF alone.
[BMC Cancer]

Full Article

Phase I Dose Escalation Study of Naive T-Cell Depleted Donor Lymphocyte Infusion following Allogeneic Stem Cell Transplantation

In this Phase I dose escalation study, the authors assessed the safety of a donor lymphocyte infusion that was depleted of CD45RA+ naive T cells.
[Bone Marrow Transplantation]


Cardiac Safe Hematopoietic Stem Cell Transplantation for Systemic Sclerosis with Poor Cardiac Function: A Pilot Safety Study that Decreases Neutropenic Interval to 5 Days

Researchers compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide transplant regimen.
[Bone Marrow Transplantation]


Use STEMvision™ for Automated Hematopoietic CFU Assay Imaging & Analysis.

Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice

Humanized mice allow in vivo characterization of the engraftment and differentiation capacities of hematopoietic stem/progenitor cell subpopulations, as well as the functional discrimination of normal and malignant stem cells.
[Trends in Immunology]



Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products for Orphan Drug Designation in the European Union for Imetelstat to Treat Myelodysplastic Syndromes

Geron Corporation announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation of its first-in-class telomerase inhibitor, imetelstat, as a potential treatment for myelodysplastic syndromes.
[Geron Corporation]

Press Release

An Optimist Takes the Helm at the National Science Foundation

The new director of the National Science Foundation (NSF), Sethuraman “Panch” Panchanathan, is familiar with the dark clouds over the agency. His boss, President Donald Trump, keeps proposing big cuts to NSF’s budget.



Allergy and Clinical Immunology Update 2020

September 26

> See All Events


Doctoral Student Position – Epigenetic and Transcriptional Regulation of Acute Myeloid Leukemia

Karolinska Institutet – Huddinge, Sweden

Postdoctoral Research Associate – Stem Cell and iPSC Biology

University of Illinois at Chicago – Chicago, Illinois, United States

Postdoctoral Researcher – RNA Epitranscriptomics and Immune Cells

Lund University – Lund, Sweden

Postdoctoral Position – Immune Privilege of the Stem Cell Niche

Columbia University – New York, New York, United States

Postdoctoral Fellow – Hematopoietic Stem Cell Biology

University of Illinois at Chicago – Chicago, Illinois, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Hematopoiesis News Twitter